BRENUS PHARMA Trademark

Trademark Overview


On Friday, January 19, 2024, a trademark application was filed for BRENUS PHARMA with the United States Patent and Trademark Office. The USPTO has given the BRENUS PHARMA trademark a serial number of 98365795. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Tuesday, August 20, 2024. This trademark is owned by BRENUS PHARMA. The BRENUS PHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Cell culture services for scientific and research purposes, for others; Chemical, biochemical, biological and bacteriological research and analysis; Development and establishment of testing specifications and procedures in the field of medicine; Medical and scientific research in the field of pharmacology; Medical research laboratory services; Medical research laboratory services in the field of oncology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical research information in the field of pharmaceuticals; Providing scientific information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Research and development in the field of immunotherapy; Research and development in the field of oncology; Research and development in the field of biotechnological and pharmaceutical drugs; Research and development in the field of advanced therapy drugs; Research and de...
brenus pharma

General Information


Serial Number98365795
Word MarkBRENUS PHARMA
Filing DateFriday, January 19, 2024
Status653 - SUSPENSION LETTER - MAILED
Status DateTuesday, August 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


NOT AVAILABLE"PHARMA"
Goods and ServicesCell culture services for scientific and research purposes, for others; Chemical, biochemical, biological and bacteriological research and analysis; Development and establishment of testing specifications and procedures in the field of medicine; Medical and scientific research in the field of pharmacology; Medical research laboratory services; Medical research laboratory services in the field of oncology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical research information in the field of pharmaceuticals; Providing scientific information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Research and development in the field of immunotherapy; Research and development in the field of oncology; Research and development in the field of biotechnological and pharmaceutical drugs; Research and development in the field of advanced therapy drugs; Research and development in the field of pharmaceuticals; Research in the field of cell engineering technology; Scientific laboratory services; Scientific research for medical purposes in the field of immunotherapy

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 19, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBRENUS PHARMA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressClermont-Ferrand 63000
FR

Trademark Events


Event DateEvent Description
Friday, January 19, 2024NEW APPLICATION ENTERED
Thursday, July 25, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 14, 2024ASSIGNED TO EXAMINER
Tuesday, August 20, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, August 20, 2024SUSPENSION LETTER WRITTEN
Tuesday, August 20, 2024LETTER OF SUSPENSION E-MAILED
Wednesday, August 28, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED